ELISA (Enzyme-Linked Immunosorbent Assay) is one of the most commonly used protein quantification techniques in the lab, prized for its high sensitivity and specificity. However, behind its seemingly straightforward protocol lie numerous pitfalls that can lead to experimental failure. Whether it's weak signal, high background, or poor reproducibility, these issues are a major headache.

In September 2025, a research paper titled "Targeting necrotic lipid release in tumors enhances immunosurveillance and cancer immunotherapy of glioblastoma" in the journal Cell Research. This study reveals for the first time a novel immune evasion mechanism whereby loss of pro-apoptotic tumor suppressor genes (such as TP53) triggers mPTP-dependent necrosis, releasing APOE-containing lipid particles that lead to T cell dysfunction. Furthermore, it proposes that clearing excess APOE lipid particles from the immune microenvironment is a new strategy to restore the function of tumor-infiltrating T cells and enhance the efficacy of immunotherapy for glioblastoma (GBM).

Virus-like particles (VLPs) are nano-sized particles formed by the self-assembly of viral structural proteins. They lack the viral genetic material, are non-infectious, and exhibit an excellent safety profile. VLPs mimic the native conformation and repetitive surface antigen array of viruses, enabling potent activation of both B cells and T cells. Consequently, they are widely used in vaccine development and antigen presentation. Researchers can produce VLPs in the laboratory by expressing recombinant viral proteins in various expression systems, including prokaryotic cells, yeast, insect cell lines, plant cells, and mammalian cell lines

On October 6th local time, the Karolinska Institute in Sweden announced that the 2025 Nobel Prize in Physiology or Medicine would be awarded to American scientists Mary E. Brunkow, Fred Ramsdell, and Japanese scientist Shimon Sakaguchi, in recognition of their groundbreaking discoveries concerning peripheral immune tolerance. The laureates will share the prize money of 11 million Swedish kronor.

Recently, a team led by Michael Demetriou at the University of California, Irvine, published a study in Cell titled "Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens." The research team proposed a novel, broad-spectrum cancer immunotherapy strategy. By achieving "Velcro-like" high-affinity targeting of Tumor-Associated Carbohydrate Antigens (TACAs), they enabled efficient killing of various cancers while avoiding the "on-target, off-cancer" toxicity common in traditional immunotherapies. This approach offers new therapeutic hope for solid and hematological tumors that currently lack effective targets.

In the field of immunology, immunoglobulin G (IgG) is widely regarded as the workhorse of humoral immunity. As the most abundant antibody in mammalian serum, it plays a critical role in defending against pathogenic infections.

In November 2025, multiple AntibodySystem products once again received broad recognition from the global research community. These products were cited in leading peer‑reviewed journals, including Nature Communications and Journal of Nanobiotechnology. The cited studies span a wide range of cutting‑edge research areas, such as the replication mechanisms of monkeypox virus, novel therapeutic strategies for psoriasis, FcγRI antibody–mediated cellular signaling, the synergistic effects of immune checkpoint blockade and ferroptosis, and the molecular basis of CREB1–DNA binding activity. Collectively, these publications highlight the critical value of AntibodySystem reagents in both fundamental life‑science research and translational medicine.

In October 2025, AntibodySystem products continues to gain recognition within the global research community, with our products cited in recent publications across prestigious journals including Advanced Science and Cell Reports. The research encompasses several cutting-edge areas, showcasing the critical role our reagents play in advancing both basic and translational life science research—from novel therapeutic strategies for Graves' ophthalmopathy and uncovering mechanisms in temporal lobe epilepsy, to elucidating mpox virus replication, developing antibodies against emerging henipaviruses, dissecting the tumor microenvironment in colorectal cancer, and characterizing the functional constraints of the Nipah virus fusion protein.

Globally, measles cases are trending upwards in North America, the European Union, and the United Kingdom. The United States is currently facing its most severe measles outbreak since declaring the disease eliminated in 2000. According to the latest data released by the Centers for Disease Control and Prevention (CDC) on the 22nd, the U.S. has reported 1,618 confirmed measles cases so far this year, resulting in 198 hospitalizations and 3 deaths. This marks the highest number of confirmed cases in the past 33 years, surpassing the previous record of 1,274 cases set in 2019. The outbreak primarily affects children under five years of age, with approximately 92% of patients being unvaccinated or having an unknown vaccination status.

October 29th each year marks World Stroke Day. Established by the World Stroke Organization (WSO), it was initiated in 2006 and officially launched in 2007. This day aims to raise global awareness about stroke—a preventable and treatable disease—and to mobilize governments, healthcare institutions, and the public to take preventive and treatment measures. The global core slogan set by WSO for 2025 is "Every Minute Counts. Know the signs of stroke. Act FAST."

The 2025 Northern Hemisphere influenza season is characterized by a notably early onset. Surveillance data from both domestic and international sources indicate that the Influenza A(H3N2) virus has become the predominant circulating strain, presenting a challenging prevention and control situation.

In August 2025, AntibodySystem products continued to provide key support for scientific research breakthroughs in multiple fields worldwide. Its products have been successively cited by authoritative academic journals such as Cell Research, Advanced Science, Cell Proliferation, Scientific Reports, and Cell Reports Methods. The research content covers various cutting-edge fields, including the development of new detection technologies for protein-protein interactions (APPLE-MS), the molecular mechanism of asthma induced by nanoplastics, the pathological regulation of bisphosphonate-related osteonecrosis of the jaw, the improvement of renal interstitial fibrosis in diabetic nephropathy by dihydroartemisinin, and the discovery of glioma immune escape mechanisms and immunotherapeutic targets!

Cervical cancer ranks as the fourth most common cancer among women globally and is caused by persistent infection with the Human Papillomavirus (HPV), a small DNA virus known to infect the skin, genital areas, and throat. Based on disease severity, HPV is categorized into low-risk and high-risk types. Persistent infection with high-risk HPV, particularly types 16 and 18, is responsible for 70% of cervical cancer cases due to their potential to cause malignant tumors.

Glycosylation is a common post-translational modification in eukaryotic cells that plays a crucial role in protein folding, stability, activity, and intercellular signaling.

AntibodySystem offers a voucher program

Premium Influenza and RSV Proteins & Antibodies

The recent surge in bispecific antibodies

Eastern equine encephalitis virus